Table 2.
Prevalence of plasma antibodies in women with borderline ovarian tumors, epithelial ovarian cancer, and other pelvic malignancies compared with matched controls and women with benign conditions.
| Tumors and antibodies analyzed | Antibody-positive n (%) | Casesa versus matched controlsb, P value | Antibody-positive n (%) | Cases versus benign conditions, P value | ||
|---|---|---|---|---|---|---|
| BOT | Casesa (n = 12) | Matched controlsb (n = 48) | Cases (n = 16) | Benign conditions (n = 209) | ||
| C. trachomatis IgG | 4 (33%) | 9 (19%) | .3 | 5 (31%) | 51 (24%) | .5 |
| cHSP60 IgG | 4 (33%) | 11 (23%) | .5 | 5 (31%) | 48 (24%), n = 202c | .5 |
| M. genitalium IgG | 4 (33%) | 2 (4%) | .01 | 4 (25%) | 17 (8%) | .049 |
| EOC | Casesa (n = 45) | Matched controlsb (n = 180) | Cases (n = 54) | Benign conditions (n = 209) | ||
| C. trachomatis IgG | 9 (20%) | 26 (14%) | .4 | 9 (17%) | 51 (24%) | .2 |
| cHSP60 IgG | 10 (22%) | 38 (22%), n = 172c | 1.0 | 13 (24%) | 48 (24%), n = 202c | 1.0 |
| M. genitalium IgG | 4 (9%) | 6 (3%) | .1 | 4 (7%) | 17 (8%) | 1.0 |
| Other pelvic malignancies | Casesa (n = 11) | Matched controlsb (n = 43) | Cases (n = 12) | Benign conditions (n = 209) | ||
| C. trachomatis IgG | 1 (9%) | 8 (19%) | .7 | 1 (8%) | 51 (24%) | .3 |
| cHSP60 IgG | 3 (27%) | 10 (23%) | 1.0 | 3 (25%) | 48 (24%), n = 202c | 1.0 |
| M. genitalium IgG | 0 | 1 (2%) | 1.0 | 0 | 17 (8%) | .6 |
| EOC with prospective plasma samplesd | Casesa (n = 10) | Matched controlsb (n = 40) | Cases (n = 11) | Benign conditions (n = 209) | ||
| C. trachomatis IgG | 2 (20%) | 4 (10%) | .6 | 2 (18%) | 51 (24%) | 1.0 |
| cHSP60 IgG | 6 (60%) | 10 (26%), n = 38c | .06 | 7 (64%) | 48 (24%), n = 202c | .008 |
| M. genitalium IgG | 0 (0%) | 1 (2.5%) | 1.0 | 0 (0%) | 17 (8%) | 1.0 |
BOT: borderline ovarian tumors; EOC: epithelial ovarian cancer.
aCases with matched controls available.
bFour controls per case from the NSHDS (Northern Sweden Health and Disease Study) were matched with respect to age and date of plasma-sampling.
cA few subjects had cHSP60 IgG antibody results that were indeterminant and therefore excluded from the statistical analyses. Assigning them extreme values (all positive or negative) did not change the main outcomes.
dEpithelial ovarian cancer with plasma samples drawn 1.3 to 5.1 years prior to diagnosis.
Pearson Chi-square, and when the expected frequency was <5, Fisher's exact test was used.